Novel glaucoma solution enters trials

Both trials failed to meet their primary endpoints for treatment of age-related macular degeneration

A pivotal phase 3 clinical trial found that SYD-101 met its 3-year primary endpoint for slowing paediatric myopia progression

Hematologists and ophthalmologists could work together for earlier diagnoses, research findings indicate

This year, the COPHy meeting moves beyond retina, addressing uveitis, neuro-ophthalmology and glaucoma in Seville, Spain

Researchers assessed the costs to patients and caregivers in Germany, Bulgaria and the US